TROG 94.01/AGITG IG9401 - Oesophagus - Localised Resectable (IG9401)

By w.paterson
15 August, 2021
0 Comments

A Randomised Phase III Clinical Trial Comparing Surgery Alone with Concurrent Preoperative Chemotherapy and Radiation Followed by Surgery For Localised Resectable Carcinoma of the Oesophagus

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Collaborating Groups

Australasian Gastro-Intestinal Cancer Trials Group (AGITG)

SOCRATES HCC trial - all Australian sites open

5 March, 2025

All Australian sites open for SOCRATES HCC trial

5 March 2025: TRIAL UPDATE We’re excited to have

4 March, 2025

TRIAL IN FOCUS: DCIS delivers valuable evidence

4 March 2025: A decade on from the last

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Randomised Phase III Clinical Trial Comparing Surgery Alone with Concurrent Preoperative Chemotherapy and Radiation Followed by Surgery For Localised Resectable Carcinoma of the Oesophagus

TROG 95.01 – Rectal Cancer

TROG 92.01 – PCNSL (Phase II)

Related Post

All Australian sites open for SOCRATES HCC trial

TRIAL IN FOCUS: DCIS delivers valuable evidence

TROG 94.01/AGITG IG9401 – Oesophagus – Localised Resectable (IG9401)

A Randomised Phase III Clinical Trial Comparing Surgery Alone with Concurrent Preoperative Chemotherapy and Radiation Followed by Surgery For Localised Resectable Carcinoma of the Oesophagus

TROG 95.01 – Rectal Cancer

TROG 92.01 – PCNSL (Phase II)

Related Post

All Australian sites open for SOCRATES HCC trial

TRIAL IN FOCUS: DCIS delivers valuable evidence